Skip to main content

Table 2 Effects of zafirlukast in asthmatic subjects maintained on β2-agonists alone

From: Tolerance and rebound with zafirlukast in patients with persistent asthma

  β2-agonists alone + Placebo Change from baseline β2-agonists alone + Zafirlukast Change from baseline
  Baseline (N = 7) Weeks 0–5 (N = 6) Weeks 6–10 (N = 5) Week 11–12 (N = 5) *W/D (N = 5) Baseline (N = 14) Weeks 0–5 (N = 13) Weeks 6–10 (N = 12) Week 11–12 (N = 12) *W/D (N = 11)
Daily PEFR a.m., L/min 375 (± 36.7) -17.3 (± 8.6) -12.2 (± 10.3) +0.8 (± 7.5) -1.2 (± 4.3) 408 (± 30.9) +14.9 (± 7.9) +1.6 (± 8.5) -3.2 (± 11.5) -30.7 (± 10.9)
Daily PEFR p.m., L/min 374 (± 35.0) +4.9 (± 6.6) +14.2 (± 10.7) +21.2 (± 11.7) -9.4 (± 8.9) 430 (± 27.4) +4.2 (± 4.4) -0.08 (± 5.7) -5.8 (± 7.5) -12.7 (± 8.2)
FEV1, mL 2.82 (± 0.33) -170 (± 80) +20.0 (± 10) -258 (± 213) +7.2 (± 128) 2.90 (± 0.16) +110 (± 60) -12.5 (± 6.9) +14.2 (± 72) -214 (± 69.8)
β2-agonist use per day 4.6 (± 0.9) -0.7 (± 0.3) -1.3 (± 0.4) -0.6 (± 0.5) +0.2 (± 0.5) 3.7 (± 0.5) -0.7 (± 0.4) -0.4 (± 0.5) +0.2 (± 0.5) +0.6 (± 0.3)
Severity score 1.9 (± 0.05) -0.2 (± 0.1) -0.3 (± 0.1) -0.2 (± 0.2) -0.04 (± 0.2) 1.8 (± 0.08) -0.2 (± 0.1) -0.2 (± 0.1) -0.2 (± 0.2) +0.3 (± 0.2)
**Total mornings 4.1 (± 1.0) -0.07 (± 0.5) -0.2 (± 0.3) -0.8 (± 0.4) -0.2 (± 0.5) 3.5 (± 0.7) -1.1 (± 0.5) -0.8 (± 0.6) -0.3 (± 0.7) +0.1 (± 0.5)
**Total awakenings 3.7 (± 1.3) -1.1 (± 0.7) -0.3 (± 1.7) +0.7 (± 2.4) -0.2 (± 0.7) 1.4 (± 0.5) -0.8 (± 0.4) -0.9 (± 0.5) +0.2 (± 0.7) +0.9 (± 0.8)